ASSEMBLY BIOSCIENCES, INC. — Form 8-K/A
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 62/100
What the filing says
Assembly Biosciences completed a $115M gross financing in Q2 2026 to fund pipeline advancement. The company expanded ABI-6250 into cholestatic liver diseases (PBC, PSC) with Phase 2 anticipated Q1 2027. Gilead selected GS-1179 for Phase 2 in recurrent genital herpes by end-2026; Assembly retains a 40% U.S. cost-profit share option. Cash runway extended to 2029, including a $75M milestone payment from Gilead due Q4 2026. Q2 revenue was $13.4M (vs. $9.6M YoY), net loss $3.9M ($0.20/share) vs. $10.2M loss YoY. Cash, equivalents, and marketable securities totaled $320.4M at June 30, 2026.
Why this rating
Major financing and extended runway materially strengthen balance sheet relative to $98M market cap; program expansion and Gilead validation meaningful but clinical-stage; positive but execution-dependent outlook.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.